– Luigi Taranto Montemurro, M.D., company’s Medical Director to discuss pharmacotherapy options for OSA – CAMBRIDGE, Mass. November 30, 2020 – Apnimed, a clinical-stage pharmaceutical company focused on advancing oral medicines to treat Obstructive Sleep Apnea (OSA)...
CAMBRIDGE, Mass. November 30, 2020 – Apnimed, a clinical-stage pharmaceutical company focused on advancing medicines to treat Obstructive Sleep Apnea (OSA) and related disorders, today announced that Larry Miller, M.D., Chief Executive Officer, will participate in a...
– Data from this study anticipated in first half of 2021 – – AD109 is a disease-modifying therapeutic for the treatment of Obstructive Sleep Apnea – –1-month open label extension study to be conducted following double-blind placebo-controlled study to demonstrate...
– Seasoned finance executive Michael Rogers joins as company’s Chief Financial Officer – – Former Biotech CEO and senior Merck executive James (Jay) Galeota joins Board of Directors – CAMBRIDGE, Mass. November 10, 2020 – Apnimed, a clinical-stage pharmaceutical...
– Data show favorable safety and pharmacokinetic profile for key component of AD109 – – Lead program AD109 advancing into a Phase 2 study before year end – CAMBRIDGE, Mass. September 17, 2020 – (BUSINESSWIRE) – Apnimed, a clinical-stage pharmaceutical company focused...
CAMBRIDGE, Mass. September 17, 2020 – (BUSINESSWIRE) – Apnimed, a clinical-stage pharmaceutical company focused on advancing medicines to treat sleep apnea and related disorders, today announced its Scientific Advisory Board (SAB). The SAB will help guide the...
